Hastrup H[au] - Search Results

Year	Number of Results
1958	1
1996	1
2001	2
2002	2
2003	1
2004	1
2008	1
2012	1
2014	1
2015	1
2016	1
2022	0

1

Treatment intensification without improved HbA1c levels in children and adolescents with Type 1 diabetes mellitus.

Sildorf SM, Hertel NT, Thomsen J, Fredheim S, Hastrup H, Pipper C, Hertz B, Svensson J; Danish Study Group of Diabetes in Children. Sildorf SM, et al. Among authors: hastrup h. Diabet Med. 2016 Apr;33(4):515-22. doi: 10.1111/dme.12900. Epub 2015 Oct 6. Diabet Med. 2016. PMID: 26333180

2

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.

Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H. Heise T, et al. Among authors: hastrup h. Diabetes Obes Metab. 2012 Oct;14(10):944-50. doi: 10.1111/j.1463-1326.2012.01638.x. Epub 2012 Jul 10. Diabetes Obes Metab. 2012. PMID: 22726241 Free article. Clinical Trial.

3

Glycine transporter dimers: evidence for occurrence in the plasma membrane.

Bartholomäus I, Milan-Lobo L, Nicke A, Dutertre S, Hastrup H, Jha A, Gether U, Sitte HH, Betz H, Eulenburg V. Bartholomäus I, et al. Among authors: hastrup h. J Biol Chem. 2008 Apr 18;283(16):10978-91. doi: 10.1074/jbc.M800622200. Epub 2008 Feb 5. J Biol Chem. 2008. PMID: 18252709 Free PMC article.

4

Zn(2+) site engineering at the oligomeric interface of the dopamine transporter.

Norgaard-Nielsen K, Norregaard L, Hastrup H, Javitch JA, Gether U. Norgaard-Nielsen K, et al. Among authors: hastrup h. FEBS Lett. 2002 Jul 31;524(1-3):87-91. doi: 10.1016/s0014-5793(02)03008-9. FEBS Lett. 2002. PMID: 12135746 Free article.

5

Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus.

Korsatko S, Deller S, Mader JK, Glettler K, Koehler G, Treiber G, Urschitz M, Wolf M, Hastrup H, Søndergaard F, Haahr H, Pieber TR. Korsatko S, et al. Among authors: hastrup h. Drugs Aging. 2014 Jan;31(1):47-53. doi: 10.1007/s40266-013-0138-0. Drugs Aging. 2014. PMID: 24263619 Free PMC article. Clinical Trial.

6

NK1 receptor fused to beta-arrestin displays a single-component, high-affinity molecular phenotype.

Martini L, Hastrup H, Holst B, Fraile-Ramos A, Marsh M, Schwartz TW. Martini L, et al. Among authors: hastrup h. Mol Pharmacol. 2002 Jul;62(1):30-7. doi: 10.1124/mol.62.1.30. Mol Pharmacol. 2002. PMID: 12065752

7

Two active molecular phenotypes of the tachykinin NK1 receptor revealed by G-protein fusions and mutagenesis.

Holst B, Hastrup H, Raffetseder U, Martini L, Schwartz TW. Holst B, et al. Among authors: hastrup h. J Biol Chem. 2001 Jun 8;276(23):19793-9. doi: 10.1074/jbc.M100621200. Epub 2001 Feb 22. J Biol Chem. 2001. PMID: 11279104 Free article.

8

Surface targeting of the dopamine transporter involves discrete epitopes in the distal C terminus but does not require canonical PDZ domain interactions.

Bjerggaard C, Fog JU, Hastrup H, Madsen K, Loland CJ, Javitch JA, Gether U. Bjerggaard C, et al. Among authors: hastrup h. J Neurosci. 2004 Aug 4;24(31):7024-36. doi: 10.1523/JNEUROSCI.1863-04.2004. J Neurosci. 2004. PMID: 15295038 Free PMC article.

9

Septide and neurokinin A are high-affinity ligands on the NK-1 receptor: evidence from homologous versus heterologous binding analysis.

Hastrup H, Schwartz TW. Hastrup H, et al. FEBS Lett. 1996 Dec 16;399(3):264-6. doi: 10.1016/s0014-5793(96)01337-3. FEBS Lett. 1996. PMID: 8985159 Free article.

10

The human dopamine transporter forms a tetramer in the plasma membrane: cross-linking of a cysteine in the fourth transmembrane segment is sensitive to cocaine analogs.

Hastrup H, Sen N, Javitch JA. Hastrup H, et al. J Biol Chem. 2003 Nov 14;278(46):45045-8. doi: 10.1074/jbc.C300349200. Epub 2003 Sep 30. J Biol Chem. 2003. PMID: 14519759 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results